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Available online 26 June 2019Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular de-
posits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggre-
gate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main
therapeutic approacheswould be to impair Aβ assembly into oligomers andﬁbrils and topromote disaggregation
of the preformed aggregate. Albumin is themost abundant protein in the cerebrospinal ﬂuid and it was reported
to bind Aβ impeding its aggregation. In a previous work we identiﬁed a 35-residue sequence of clusterin, a well-
known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the
docking experiments show that the average binding free energy of the CTerm-Aβ1–42 simulations was signiﬁ-
cantly lower than that of the clusterin-Aβ1–42 binding, highlighting the possibility that the CTerm retains
albumin's binding properties. To validate this observation, we performed in vitro structural analysis of soluble
and aggregated 1 μMAβ1–42 incubated with 5 μMCTerm, equimolar to the albumin concentration in the CSF. Re-
versed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ1–42 aggregates
when the CTermwas present. Furthermore, we treated a human neuroblastoma cell linewith soluble and aggre-
gated Aβ1–42 incubatedwith CTerm obtaining a signiﬁcant protection against Aβ-induced neurotoxicity. These in
silico and in vitro data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassem-
ble of Aβ aggregates protecting neurons.
© 2019 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
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Alzheimer's disease (AD) histopathological hallmarks are the extra-
cellular aggregation of amyloid β-peptide (Aβ) in the brain, and the
intraneuronal aggregation of hyperphosphorylated tau protein [1,2].
The amyloid cascade hypothesis proposes that Aβ aggregation into olig-
omers andﬁbrils induces synaptotoxicity and ultimately neuronal death
[3–5].
The Aβ is a ~4 kDa peptide released from the amyloid precursor pro-
tein (APP) [6] by the sequential action of the enzymes β- and γ-
secretases [7,8]. Aβ is produced thoughout the life of an individual,
being physiologically degraded in the brain by different enzymes or
cleared through the blood brain barrier into the blood [9]. During
aging there is an increase in Aβ production and an impairment of Aβ
clearance from brain to blood [10], favoring its aggregation into β-
sheets. Then, Aβ forms oligomers known to be highly neurotoxic [3,4],
and they progress into forming amyloid ﬁbrils that are packed into se-
nile plaques.
At present, AD prevalence is increasing as the world population
ages [11] and has become a major health and social problem ex-
pected to reach pandemic status by 2050 [12]. Unfortunately, de-
spite the current knowledge on APP processing, there are no
treatments that effectively prevent AD development or its progres-
sion. On the other hand, the use of antibodies against Aβ to disas-
semble cerebral Aβ aggregates [13–15] has not yielded positive
results in clinical trials.
Interestingly, clusterin (also termed apolipoprotein J) and albumin
are cerebral proteins that have been reported to bind Aβ under physio-
logical conditions [16–18]. In fact, clusterin impairs Aβ aggregation in
the brain [16] and some clusterin polymorphisms are major risk factors
for late onset AD [19]. Albumin has also been demonstrated to inhibit
Aβ aggregation [20–23]. These ﬁndings make the study of clusterin
and albumin of high relevance to understand AD etiology and to eluci-
date mechanisms of neuroprotection in AD.
Albumin is the most abundant protein in the cerebrospinal ﬂuid
(CSF) producedmostly by ultraﬁltrate of plasma proteins [24] andmin-
imally by the microglia [25]. It is a single peptide chain of 585 amino
acids with a secondary structure containing 67% α-helix, 23% extended
chain and 10% β-sheet [26–28]. Albumin is a ﬂexible molecule, with the
ability to change its structure depending on environmental conditions
such as temperature, pH or ionic strength [29,30]. It can bind a plethora
of differentmolecules [30–33], and it can even act as a free radical scav-
enger [34]. More speciﬁcally, albumin can bind Aβ [20,35,36] and is re-
sponsible for 95% of its transport in the blood [18,37,38], thereby
regulating the amount of circulating Aβ.
Previously, we used the Protein-Protein Interface Prediction Server
(iFRAG) to predict the interaction for short protein fragments and
found that clusterin shares a common sequence with the C-terminus
domain of human albumin (CTerm; Fig. S1) [39]. Here, we address the
effect of its CTerm in Aβ aggregation using in silico and in vitro
techniques.
Computational methods to predict and evaluate protein-protein in-
teractions (PPIs) represent a feasible alternative to experimental ap-
proaches. Although docking experiments are currently used to
predict the conformation of PPIs [40], it has been shown that the dis-
tribution of scores of different docking populations could be used to
discern between interacting and non-interacting protein pairs. This is
valid even when the native conformation cannot be identiﬁed
among the poses [41] and the population of docking poses can be
used to predict the binding energy if the structure of the complex is
unknown [42]. In this work, we used similar principles to assess the
binding potential of clusterin, albumin and the CTerm to the alpha
and beta conformations of the Aβ1–42 peptide. We focused our efforts
on elucidating the physiological relevance of the CTerm and itsinteraction with Aβ1–42 peptide by in vitro experiments using different
techniques and cell cultures.
2. Methodology
2.1. Modeling of the Clusterin Peptide
We found the four homologous sequences between clusterin and al-
bumin in a previouswork through sequence alignments [39]. Due to the
lack of available structures for clusterin or the peptide region of interest,
5 decoys of the most promising peptide according to iFrag [39] were
built with MODELLER [43–45] following the alignment shown in Fig.
1A. The ﬁve decoys were minimized and scored with Rosetta [46] and
the best-scored decoy was selected as the structural representative of
the clusterin-peptide (Fig. 1B).
2.2. Aβ1–42 -Docking Analyses
With the exception of the clusterin-peptide model, structures for all
the different elements required for the docking analyse were obtained
from the Protein Data Bank (PDB) [47]. The clusterin-peptide and the
CTerm structure (crystal structure PDB ID: 5FUO [48], residues 504-
538) were docked with two different target binders: (1) the Aβ1–42 α
conformation (nuclear magnetic resonance (NMR) ensemble PDB ID:
1IYT [49]), (2) the Aβ1–42 β conformation (cryo-EM structure PDB ID:
5OQV [50]). Additionally, CTerm was also docked to the most terminal
region of albumin (PDB ID: 5FUO, residues 539-582). to which is nor-
mally bound (CTerm-lid). This region of the wild-type albumin hides
the putative recognition site between CTerm and Aβ1–42 (Fig. 2A).
From the only two available NMR structures in the PDB [47] present-
ing the full 42 residues of the Aβ1–42 peptide, we selected 1IYT over
1Z0Q [doi:https://doi.org/10.1002/cbic.200500223] (see alignment of
resolved residue densities for all Aβ1–42 peptides in the PDB at https://
github.com/structuralbioinformatics/amyloid/blob/master/albumina/
source/alpha_amyloids/alignment.highlight.aln) for two main reasons.
On the one hand, most of the standard PDB metric qualities (namely
clashscore, Ramachandran outliers and sidechain outliers) are far better
in 1IYT than in 1Z0Q. On the other hand, 1Z0Q is described as an inter-
mediate state between theα and β conformations of Aβ1–42 while 1IYT
aims to represent the stable alpha state of the peptide.
For each pair, a total of 8000 decoys were generated with Rosetta's
docking protocol [51] and optimized with Rosetta's FastRelax [52]. De-
coys were analyzed in terms of their ddG, shape complementarity and
structural variation of the target binder.
2.3. CTerm Synthesis
The CTerm peptide, AETFTFHADICTLSEKERQIKKQTALVELVKHKPK-
amide, containing the hydrophobic domains reported to be Aβ binding
sites by García et al. [39] was produced in C-terminal carboxamide form
by Fmoc solid phase synthesis in a peptide synthesizer Prelude (Gyros
Protein Technologies). It was puriﬁed to near homogeneity (97%) by re-
versed-phase high performance liquid chromatography (HPLC).
2.4. CTerm Analysis
Analytical reversed-phase HPLC was performed on C18 columns
(4.6 × 50 mm, 3 μm; Phenomenex) in a liquid chomatrograph (LC-
2010A; Shimadzu). Solvent A was 0.045% triﬂuoroacetic acid (TFA) in
H2O; solvent B was 0.036% TFA in acetonitrile. Elution was carried out
with linear 15–50% gradients of solvent B into A over 15 min at 1 mL/
min ﬂow rate, with UV detection at 220 nm. LC-mass spectrometry
(MS) was performed in a LC-MS 2010EV instrument (Shimadzu) ﬁtted
with an XBridge column (4.6 × 150 mm, 3.5 μm; Waters), eluted with
Fig. 1. In silicomodeling of clusterin and docking comparisonwith the CTerm. A) Guiding alignment for themodeling of the clusterin peptide. Common amino acids are labelled in blue. B)
Structures of the 5 clusterin decoyswith the initial models (transparent) and theminimized structure (red). Rosetta scores for theminimized structure are shown under each structure. C)
Comparison of scores between the docking population of clusterin (or albumin) and the Aβ1–42 peptide (inα orβ conformation). Using a total of 8000 decoys on each docking population,
the scores of albuminpeptides systematically outperforms those of clusterinwhen binding the same target, with a statistical signiﬁcance of p b .001. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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0.08% formic acid in acetonitrile) over 15min at a ﬂow rate of 1 mL/min,
with UV detection at 220 nm.
2.5. CTerm Puriﬁcation
Preparative HPLC runs were performed on a Luna C18 column (21.2
mm× 250mm, 10 μm; Phenomenex), using linear 15–50% gradients of
solvent B (0.1% in acetonitrile) into A (0.1% TFA in H2O), as required,
with a ﬂow rate of 25 mL/min. Fractions of high (N95%) HPLC homoge-
neity were further characterized by electrospray mass spectrometry
using a XBridge column C18 (Waters) and a gradient at 1 mL/min of A
(0.1% formic acid in H2O) into B (0.08% formic acid in CH3CN). Detection
was performed at 220 nm. Fractions of adequate homogeneity andwith
the expected mass (4067.77 Da) were combined, lyophilized, and used
in subsequent experiments. See Figs. S2 and S3 and Table S1 for addi-
tional details.
2.6. Circular Dichroism (CD)
CTerm was dissolved in 5 mM NaOH at a stock concentration of 1
mg/mL. The peptide was further dissolved to yield a 50mM concentra-
tion in 10mM phosphate buffer at pH 7.2 in the presence or absence of
20mM SDS. The CD was performed as follows. The spectral region was
recorded from 190 to 250 nm, with a 0.5 nm step resolution, on a Jasco
J-715 CD spectropolarimeter (Jasco Inc.) using a quartz cell of 1.0 mm
optical path length at room temperature. The scanning speed was 100
nm/min with 2 s time response, and the spectra were collected and av-
eraged over 10 scans. Secondary structure estimation derived from CD
data was assessed using K2D3 [53].2.7. Amyloid Preparation
Lyophilized Aβ1–42 (Anaspec) was solubilized as previously de-
scribed [54]. Brieﬂy, 1 mg Aβ was dissolved in 250 μL of MilliQ water
and pHwas adjusted to ≥10.5 using 1 MNaOH solution to avoid the iso-
electric point of Aβ disassembling and aggregates that may be present.
Peptides were diluted in 250 μL of 20 mM phosphate buffer (pH 7.4).
Furthermore, the solutions were sonicated for 1 min in a bath-type
sonicator (Bioruptor, Diagenode). The preparations were immediately
used for aggregation or stored in 25 μL aliquots at−20 °C until used.
2.8. Reversed-Phase Chromatography Analysis of CTerm Effect on Aβ
Aggregation
Soluble and pre-aggregated (24 h at 37 °C) 1 μM Aβ1–42 was dis-
solved in Ham's F12 medium and incubated in the presence/absence
of 5 μM CTerm at 37 °C during 24 h for assembly and disassemble as-
says. Samples were quenched in 2% triﬂuoroacetic acid and injected in
a Waters 2690 HPLC coupled to a UV detector set to 214 nm. A linear
gradient of 25%–45% of 0.1% triﬂuoroacetic acid in acetonitrile was ap-
plied for 90 min into a 250 × 4.6 mm (5 μm) C4 column at a ﬂow rate
of 0.75mL/min.
2.9. Reversed-Phase Chromatography Analysis of Control Peptide Effect on
Aβ Aggregation
Random peptides with the same size that CTerm were synthetized:
peptides X, Y and Z. Soluble and pre-aggregated (24 h at 37 °C) 1 μM
Aβ1–42was dissolved in Ham's F12medium and incubated in the pres-
ence/absence of 5 μM peptides at 37 °C during 24 h for assembly and
Fig. 2. Structural in silico analysis of Aβ1–42 interaction with the CTerm. A) Structure of human albumin. The sequence of the CTerm is labelled in red. The continuing structural segment
(CTerm-lid) is shown in pink (top). Theα and β conﬁgurations of Aβ1–42 are shown at the bottom. B) Scores distribution of the docking analysis of CTerm againstα-Aβ1–42, β-Aβ1–42, and
CTerm-lid. C) Individual contribution of the residues of the CTerm to the binding according to the top 200 decoys (2.5% of the total). D) Representation of theﬁrst ﬁve top-scored decoys of
the docking between the amyloid peptide (blue) and the CTerm (red). ddG score and shape complementarity are provided under each structure. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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C18 columns (4.6 × 50 mm, 3 μm, Phenomenex) in a model LC-2010A
system (Shimadzu). Solvent A was 0.045% TFA in H2O; solvent B was
0.036% TFA in acetonitrile. Elution was carried out with linear 5–95%
gradients of solvent B into A over 15 min at 1 mL/min ﬂow rate, with
UV detection at 220 nm.2.10. Transmission Electron Microscopy (TEM)
Soluble and pre-aggregated (24 h at 37 °C) 1 μM Aβ1–42 was dis-
solved in Ham's F12 medium and incubated in the presence/absence
of 5 μM CTerm at 37 °C during 24 h for assembly and disassemble as-
says. Samples of aggregated peptides obtained as described above
were placed onto carbon-coated 200 mesh copper grids and incubated
for 5 min. The grids were washed with distilled water and negatively
stained with 2% (w/v) uranyl acetate for 2 min. Micrographs wereobtained in a JEM-1010 (JEOL) transmission electron microscope oper-
ated at 80 kV accelerating voltage and equipped with an Orius CCD
camera.
2.11. Cell Viability Assay by MTT Reduction
A human neuroblastoma cell line (SH-SY5Y cells) was seeded in
poly-L-lysine coated 96-well plates at a concentration of 2 × 104 cells/
well. Soluble and pre-aggregated (24 h at 37 °C) 1 μM Aβ1–42 was dis-
solved in Ham's F12 medium and incubated in the presence/absence
of 5 μM CTerm at 37 °C during 24 h for assembly and disassemble as-
says. After they were ready the samples were added. Cells were treated
with the different samples during 24 h at 37 °C. Cell viability was tested
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction. 10% v/v of MTT stock solution (5 mg/mL) was added.
After 2 h the media was replaced with 100 μL of dimethylsulfoxide.
MTT absorbance was determined in an Inﬁnite 200 multiplate reader
967P. Picón-Pagès et al. / Computational and Structural Biotechnology Journal 17 (2019) 963–971at A540nmand corrected by A650nm. Data are shown compared to un-
treated controls (100%).
2.12. Aβ1–42 Binding to Neuronal Processes
Primary cultures were carried out as previously reported [4]. The
procedure was previously approved by the Ethics Committee of the
Institut Municipal d'Investigacions Mèdiques-Universitat Pompeu
Fabra (EC-IMIM-UPF). Cortical neurons were isolated from 18-day-old
OF1 mouse embryos. The brain was removed and the cortex aseptically
dissected on ice-cold Hanks' balanced salt solution supplemented with
4.5 g/L glucose and trypsinized for 17min at 37 °C. In order to eliminate
rests of the trypsinizationmedium and to disaggregate the cells, the cell
solution was washed thrice in Hanks' balanced salt solution+glucose
and mechanically dissociated. Then, cells were seeded on poly-D-lysine
coated coverslips in 24 well-plates with DMEMmedium plus 10% horse
serum at 105 cells/well. Once neurons were attached to the
polylysinated wells (2 h), the seeding medium was removed and
Neurobasal medium was added containing 2% B27 supplement, 1%
GlutaMAX and 1% penicillin/streptomycin. On day 3 of in vitro culture,
cells were treated with 2 μM 1-β-D-arabinofuranosylcytosine for 24 h
to eliminate glia. Primary cortical neurons were used at day 10 [15].
Cells were treated for 10 min at room temperature in mild agitation
with 10 μM HiLyte Fluor488 labelled human Aβ1–42 (fAβ1–42)
preformed in the presence/absence of 20 μMCTerm. After three washes
with phosphate-buffered saline (PBS) cells were incubated on ice with
75 μg/mL red concanavaline in neurobasal medium for 20 min. Then
cells were washed again in cold PBS and ﬁxed in 4% paraformaldehyde
in PBS before mounting. Images were obtained in a SP5 Leica confocal
microscope using 40× objective. Image ﬂuorescence analysis was per-
formed using Image J software.
2.13. Statistical Analysis
Data are expressed as the mean ± SEM of the values from the num-
ber of experiments as indicated in the corresponding ﬁgures. Student's
t-test or one-way analysis of variance (ANOVA) with Bonferroni multi-
ple comparisons test were used for statistical analyses.
3. Results
3.1. Albumin Binds Aß With Higher Afﬁnity Than Clusterin
Clusterin is known to bind and to inhibit Aβ aggregation [16], in fact
some polymorphisms that cause the dysfunction of this protein are a
major risk factor for late onset AD [19]. We used Aβ1–42 in in silico and
in vitro experiments because it is the most aggregation-prone species
of Aβ peptide and, therefore the most neurotoxic in humans [55]. The
comparison of the binding afﬁnities of the clusterin peptides and the
CTerm to both the alpha and beta conformations of the Aβ1–42 (Fig.
1C) shows that the four combinations have relatively acceptable ΔG
values. Still, albumin's CTerm peptide systematically obtained signiﬁ-
cantly better scores (p b .001) for the global distribution of all poses.
This observation suggests that the CTerm peptide can bind to the Aβ1–
42 peptide with an afﬁnity equal or possibly higher than clusterin.
3.2. In silico Analysis of Aβ1–42-CTerm Interaction
A peptide region of human albumin that had been previously identi-
ﬁedwith iFRAG [39],was predicted to bind toAβ1–42. The iFRAGmethod
predicts putative fragments that participate in the interface of an inter-
action through the search for similar sequences of known interactions.
We run iFRAG with the albumin and clusterin sequences interacting
with the sequence of theAβ1–42 peptide.We obtained several fragments
of clusterin and human albumin that would putatively interact with
Aβ1–42. We selected the high score fragments from iFRAG and alignedthe sequences with CLUSTAL [56]. The alignment showed 40% similarity
and N25% identity, which increased to N70% on a short stretch of 7
amino-acids [39]. The analysis showed that both proteins share a com-
mon sequence located at the albumin's CTerm [39]. The CTerm domain
has 35 amino acids (AETFTFHADICTLSEKERQIKKQTALVELVKHKPK) and
shows high sequence similarity to clusterin (QNAVNGVKQIKTLIEKTN
EERKTLLSNLEEAKKKK) [39].
Here, the binding afﬁnity of the CTerm peptide was computationally
evaluated against its regular partner (CTerm-lid) and Aβ1–42 in itsα and
β conformations (Fig. 2A). The score distributions obtained from the
generated decoys (Fig. 2B) suggest a slightly higher afﬁnity for the α
conformation of Aβ1–42 than for the β, albeit far from the afﬁnity to its
normal molecular partner. Interestingly, the CTerm peptide seems to
trigger strong conformational changes when binding to the Aβ1–42 pep-
tide. While binding to the peptide in theα conformation translates into
changes between the relative position of the two α-helices, binding to
the peptide in the β conformation seems to result in a break of the β
conﬁguration that might affect the pairing with other Aβ1–42 peptides.
The evaluation of the individual contribution of each residue of the
CTerm peptide to the binding with Aβ1–42 (Fig. 2C) shows the involve-
ment of residues located throughout the entire peptide, suggesting the
need for the full peptide for the recognition of its binding partners.
When we analyzed the top 5 best scored decoys (Fig. 2D), we observed
a very similar binding conﬁguration. These conﬁgurations compete di-
rectly with the natural helix-loop-helix segment (CTerm-lid) to which
the CTerm binds. All the data concerning the docking analysis can be
found at https://github.com/structuralbioinformatics/amyloid/tree/
master/albumina. A video showing the docking of the CTerm with
Aβ1–42 is available at https://github.com/structuralbioinformatics/
amyloid/raw/master/albumina/images/albumina_top5_overlap.mp4.
To further conﬁrm the different behaviour of theα and β conforma-
tions, we docked CTerm and clusterin to the described α-β transition
state structure (PDB ID: 1Z0Q) and compare it with the results obtained
for the α (PDB ID: 1IYT) and the β (PDB ID: 5OQV) conformation (Fig.
S4). This comparison also allows to compensate for the difference in
crystallization solvents used between 1IYT and 1Z0Q. As expected
from its described condition as transition state, 1Z0Q mostly behaves
as an intermediate between the two conformations, the only exception
being the RosettaScore evaluation. This fact is not that surprising con-
sidering that some of the same metrics that deﬁne entry quality in the
PDB do affect the scoring provide by Rosetta. The differences in ddG be-
tween the binding to albumin or clusterin in 1Z0Q are lower than those
we obtained for 1IYT or the β conformation. However, it is still within
the range to support that albumin can bind to the Aβ peptide with at
least the same or better afﬁnity than clusterin.
3.3. In vitro Analysis of Aβ1–42-CTerm Interaction
We synthesized the CTerm as explained in theMethodology Section.
The CD mean residue molar ellipticity of the CTerm is shown in Fig. S5.
In solution, the peptide shows α-helical distinct features (minima at
204 and 223 nm), with α-helix secondary structure content of 56%.
SDS micelles (20 mM detergent) used as helical inducer, increases the
propensity of the CTerm secondary structure to 90%, with minima at
206 and 223 nm and a maximum at 192 nm.
Next, we showed the anti-aggregant properties of the CTerm on
Aβ1–42. CTerm was used at 5 μM, which is the physiological concentra-
tion found in human CSF. The hydrophobicity analysis of the species
present in several mixtures by reversed-phase chromatography (Fig.
3A) reveals several species. At early elution times (left of the chromato-
graph), the speciﬁc peaks due to the presence of Aβ1–42 oligomers are
absent when the CTerm is present. In addition, we observed that the
CTerm shifts the elution proﬁle to the left, towards more hydrophilic
species in the presence of Aβ1–42 oligomers when compared with the
elution proﬁle of Aβ1–42 alone (Fig. 3A,a). This behavior indicates that
the CTerm prevents the assembly of oligomeric species. Moreover, the
Fig. 3. Effect of the CTerm on Aβ1–42 assembly and disassemble in vitro. Soluble or aggregated 1 μM Aβ1–42 and 1 μM Aβ1–42 + 5 μM CTerm were incubated for 24 h to allow soluble Aβ
assembly or ﬁbrillar Aβ disassemble. A) Fractions eluted by reverse-phase chromatography. In the central part of the graph are the peaks of the high molecular weight ﬁbrils and on
the left the peaks that correspond to low molecular weight oligomers. Representative peaks in terms of hydrophobicity: 1, peak corresponding to Aβ1–42 oligomers; 2, 3, and 4, peaks
that shift their hydrophobicity in the presence/absence of Aβ1−42 ﬁbrils. A,a) Aggregation assay performed with soluble Aβ1–42. A,b) Disassemble assay performed with aggregated
Aβ1–42. Data are from a representative experiment. B) TEM images of aggregation assays. B,a) 1 μM Aβ1–42 aggregated for 24 h. Insets correspond to oligomers and protoﬁbrils. B,b) 1
μM Aβ1–42 + 5 μM CTerm aggregated for 24 h. B,c) Aggregated 1 μM Aβ1–42 + 5 μM CTerm incubated for 24 h. B,d) CTerm alone incubated for 24 h. Representative images are shown.
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high (ﬁbrils) and low (oligomers) molecular weights (Fig. 3A,b).
Three peptides of the same size as the CTerm (termed X, Y, Z) were
randomly generated to use as controls. We found that the three pep-
tides favour Aβ aggregation and stabilize the pre-existing oligomers
and ﬁbrils. The results obtained with Peptide Y, as a representative ex-
periment, are shown in Fig. S6. This pattern of interaction between Aβ
and different peptides is expected since it has been reported that the
binding of Aβ to proteins can act as seeds for amyloid aggregation and
stabilization of ﬁbrils [57–60].
Furthermore, the anti-aggregant properties of the CTermwere stud-
ied by TEM (Fig. 3B).When Aβ1–42 was incubated alone for 24 h, we ob-
served the presence of the typical amyloid unbranchedﬁbrils (Fig. 3B,a),
oligomers and protoﬁbrils (inset in Fig. 3B,a). Upon co-incubation of
Aβ1–42 with the CTerm, amorphous aggregateswere the only structures
present (Fig. 3B,b). To study the disassemble ability of the CTerm, whenAβ1–42 was prepared as in Fig. 3B, and was incubated for 24 h with the
CTerm, small ﬁbrils and amorphous aggregates were observed (Fig.
3B,c). The interference of CTerm in the analysis was discarded because
no aggregates were observed when the CTerm was incubated alone
(Fig. 3B,d). These results are in agreement with those obtained in the
experiment presented in Fig. 3A and Fig. S7.
3.4. CTerm Protects Neurons against Amyloid Neurotoxicity
Wealso studied the effect of the CTermonAβ-induced neurotoxicity
on a humanneuroblastoma cell line. These studies have been performed
with soluble Aβ1–42 incubated in the presence/absence of the CTerm for
24 h in vitro. Later, the oligomerswere added to cells for 24 h (Fig. 4A). A
signiﬁcant protection was observed when Aβ1–42 aggregates were
preformed in the presence of the CTerm (p b .05). Since Aβ aggregates,
particularly oligomers, bind to the neuronal membrane impairing its
Fig. 4. Effect of the CTerm on Aβ-induced neurotoxicity in vitro. A) Human neuroblastoma cells were treated with 1 μM Aβ1–42 or 1 μM Aβ1–42 + 5 μM CTerm, which were previously
incubated for 24 h to allow the assembly of Aβ. Cell viability was assayed by MTT reduction after 24 h. Data are the mean ± SEM from 5 independent experiments performed by
duplicate. * p b .05 and ** p b .01. B) Mouse cortical neurons were incubated with aggregated 10 μM fAβ1–42 and 10 μM fAβ1–42 + 20 μM CTerm for 10min. Binding of Aβ aggregates to
the membrane was evaluated by colocalization with membrane markers (concanavalin A staining). Representative images of fAβ1–42 (green) and concanavalin A (red). The
quantiﬁcation analysis of ﬂuorescence intensity of fAβ1–42 was normalized by concanavalin A (bottom, left). Concanavalin A ﬂuorescence was also independently analyzed (bottom,
right). Data are the mean ± SEM of 8 replicates. *** p b .001. C) Human neuroblastoma cells were treated with 1 μM Aβ1–42 and 1 μM Aβ1–42 + 5 μM CTerm, aggregates that were
previously incubated for 24 h to allow Aβ disassemble by the CTerm. Cell viability was assayed by MTT reduction after 24 h. Data are the mean ± SEM from 8 independent
experiments performed by duplicate. * p b .05 and ** p b .01. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the absence/presence of the CTerm to primary cultures of cortical neu-
rons. We used these cell cultures to study the binding of the Aβ1–42 ag-
gregates to the surface of neurites mirroring what happens in vivo.
Experiments were run with concanavalin A, a membrane marker, and
a ﬂuorescent fAβ1–42 peptide to study their colocalization (Fig. 4B). Cor-
tical neurons treatedwith fAβ1–42 aggregates (at 10 μMto allow its visu-
alization) showed higher binding to the membrane throughout the
neurite network than oligomers formed in the presence of the CTerm.
Fluorescence was quantiﬁed and the aggregates of fAβ1–42 formed in
the presence of the CTerm showed a 25% reduction in binding to neuro-
nal membranes (p b .001; Fig. 4B) while the staining for concanavalin
was not modiﬁed.
Finally, we prepared Aβ1–42 aggregates for 24 h in vitro. Then, they
were incubated with the CTerm in vitro for 24 h in order to disassemblethe oligomers. Later, human neuroblastoma cells were challenged with
these samples for 24 h (Fig. 4C). Aβ1–42 aggregate-induced neurotoxic-
ity was signiﬁcantly impaired when the Aβ1–42 aggregates were pre-in-
cubatedwith the CTerm (p b .01; Fig. 4C). The CTermalonehad no effect
on cell viability (Fig. 4D).
4. Discussion
In order to elucidate the albumin domain where the anti aggregant
Aβ property is located, we determined the regions of human albumin
that could interact with Aβ using the iFRAG procedure [39]. In our pre-
vious work we had compared the sequence of clusterin, a well-known
Aβ binding protein [16] whose polymorphisms are risk factors for late
onset AD [19] with that of albumin. We found that the albumin CTerm
has N40% similarity (70% identity on a short 7-residue stretch) with
970 P. Picón-Pagès et al. / Computational and Structural Biotechnology Journal 17 (2019) 963–971clusterin, and therefore we focused our study on the properties of this
fragment. In the present work we show in silico evidence that the
CTerm peptide produces conformational changes on Aβ1–42 upon bind-
ing. This interaction might impair Aβ1–42 conformation into β sheets
preventing oligomer and ﬁbril formation. These predictions were con-
ﬁrmed in vitro by reversed-phase chromatography and electronmicros-
copy. Moreover, the in silico results that suggest a change of the β-sheet
Aβ1–42 structure ﬁt with the ability of the CTerm to induce disassemble
of aggregated Aβ1–42, data that we obtained by reverse phase chroma-
tography and electron microscopy.
As expected, the CTerm at physiological CSF concentration was able
to protect neurons against Aβ1–42 neurotoxicity. These results are in
agreement with our ﬁndings of decreased binding of Aβ aggregates to
neuronal membranes when the CTerm is co-incubated with Aβ. Since
AD is proposed to begin with the insidious interference of Aβ oligomers
on synaptic activity [3,4], we consider that this signiﬁcant reduction in
neurotoxicity and binding of Aβ aggregates to neuronal membranes is
reinforcing the protective role of albumin CTerm in AD.
The experimental results in thiswork highlight the ability of the pro-
gram iFrag to predict new binding sites for medical relevant targets, for
example providing the new binder CTerm for Aβ peptides. Despite pre-
viously described interactions between albumin and Aβ peptides,
CTerm is a non-exposed region of the albumin and, as such, this site
had been dismissed on the prediction of the interaction by other pro-
grams. This work conﬁrms that iFrag had successfully identiﬁed a fully
new binder for Aβ peptides capable of avoiding its aggregation.
Finally, the interest in clusterin and proteins that share common se-
quences and Aβ binding properties is based on the effect of subtle
changes in their sequence, as it has been reported for clusterin [19], or
their concentrations, as it has been reported for albumin [61], which
along the life of an individual can produce a lack of protection yielding
to AD onset after 65 years old.
5. Conclusions
We propose that the CTerm is a key region of albumin that partici-
pates in the inhibition of Aβ assembly also favour disassemble of already
aggregated Aβ, due to its speciﬁc Aβ binding capacity. These ﬁndings
could set the basis for the design of inhibitory peptides as therapeutic
tools for the treatment of AD.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.csbj.2019.06.017.
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